Company: SXTPW
Filing Date: 2025-02-14
Form Type: S-1
Source: 0001213900-25-014334
Chunk: 43

Company: 60 DEGREES PHARMACEUTICALS, INC.
Filing Date: 2025-02-14
Form: S-1
Chunk 43
---
 | Patent                                                                                                                
 terms may be inadequate to protect our competitive position on our product candidates for an adequate amount of time; |

| ● | The                                                                                                                                       
 earliest Paragraph IV certification date for Arakoda has passed. Generic companies may file an ANDA at any time, and successful challenge 
 of our malaria use patents would negatively impact our business;                                                                          |

| ● | We                                                                                                                                       
 may not be able to maintain the listing of our common stock on Nasdaq, which could adversely affect our liquidity and the trading volume 
 and market price of our common stock and decrease or eliminate your investment;                                                          |

| ● | Any                                                                                                              
 failure to maintain effective internal controls over financial reporting could have an adverse impact on us; and |

| ● | We                                                                                                                                        
 are an “emerging growth company” and a “smaller reporting company” under the JOBS Act, and we cannot be certain                           
 if the reduced disclosure requirements applicable to emerging growth companies and smaller reporting companies will make our common stock 
 less attractive to investors.                                                                                                             |

Information Regarding our Capitalization As of February 14, 2025 we had 7,364,554 shares of common stock issued and outstanding. Additional information regarding our issued and outstanding securities may be found under “ Market for Common Equity and Related Stockholder Matters” and “ Description of Securities.” Unless otherwise specifically stated, information throughout this prospectus does not assume the exercise of outstanding options or warrants to purchase shares of our common stock. Corporate Information Our principal executive offices are located at 1025 Connecticut Avenue NW Suite 1000, Washington, D.C. 20036. Our corporate website address is 60degreespharma.com. Our telephone number is (202) 327-5422. The information included on our website is not part of this prospectus. Implications of Being an Emerging Growth Company and a Smaller Reporting Company We are an “emerging growth company,” as defined in the JOBS Act. We will remain an emerging growth company until the earlier of (i) the last day of the fiscal year following the fifth anniversary of the date of the first sale of our common stock pursuant to an effective registration statement under the Securities Act; (ii) the last day of the fiscal year in which we have total annual gross revenues of $1.235 billion or more; (iii) the date on which we have issued more than $1 billion in nonconvertible debt during the previous three years; or (iv) the date on which we are deemed to be a large accelerated